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Abstract
Background/Aims: Ceramide kinase (CerK) catalyzes the generation of the sphingolipid 
ceramide-1-phosphate (C1P) which regulates various cellular functions including cell growth 
and death, and inflammation. Here, we used a novel catalytic inhibitor of CerK, NVP-231, and 
CerK knockout cells to investigate the contribution of CerK to proliferation and inflammation 
in renal mesangial cells and fibroblasts. Methods: Cells were treated with NVP-231 and [3H]-
thymidine incorporation into DNA, [3H]-arachidonic acid release, prostaglandin E2 (PGE2) 
synthesis, cell cycle distribution, and apoptosis were determined. Results: Treatment of rat 
mesangial cells and mouse renal fibroblasts with NVP-231 decreased DNA synthesis, but not 
of agonist-stimulated arachidonic acid release or PGE2 synthesis. Similarly, proliferation but 
not arachidonic acid release or PGE2 synthesis was reduced in CERK knockout renal fibroblasts. 
The anti-proliferative effect of NVP-231 on mesangial cells was due to M phase arrest as 
determined using the mitosis markers phospho-histone H3, cdc2 and polo-like kinase-1, 
and induction of apoptosis. Moreover, loss of CerK sensitized cells towards stress-induced 
apoptosis. Conclusions: Our data demonstrate that CerK induces proliferation but not PGE2 
formation of renal mesangial cells and fibroblasts, and suggest that targeted CerK inhibition 
has potential for treating mesangioproliferative kidney diseases.
O. Pastukhov  and S. Schwalm contributed equally
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IntroductionMesangial cells are specialized cells localized in the renal glomerulus that exert important functions such as preserving the structural integrity of the glomerulus, and regulating 
the glomerular filtration rate by their smooth muscle cell-like contractile properties. In addition, mesangial cells also play a central role in various pathological processes of the 
renal glomerulus [1-3]. Mesangial cells are activated by classical pro-inflammatory cytokines 
including interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα). Upon activation, 
they respond with a variety of reactions which are considered hallmarks of many forms of 
chronic inflammatory kidney diseases, including accelerated proliferation, increased pro-
inflammatory mediators production, and enhanced extracellular matrix production [1, 3].
A key event commonly associated with inflammation is the production of prostaglandin E2 (PGE2) by sequential activation of phospholipases A2 (PLA2) and cyclooxygenases (COX). 
This has attracted attention due to the broad clinical impact of anti-inflammatory drugs. 
Best reported are COX inhibitors such as aspirin which have been used for many years. In 
addition, alternative approaches have been described such as inhibition of PLA2, which represents an attractive target due to the fact that the activity of this class of enzymes is the 
rate-limiting step in PGE2 formation. However, the development of PLA2 inhibitors turned 
out to be difficult due to the large number of isoforms which are redundantly involved in 
inflammatory reactions [4-8]. Sphingolipids are crucial not only for providing structural support to cellular 
membranes, but also as signalling molecules in many biological systems, and previous 
studies demonstrated a regulatory function of sphingosine 1-phosphate (S1P) in various 
physiological and pathophysiological processes [9, 10].
Recently, another phosphorylated lipid, i.e. ceramide 1-phosphate (C1P), was proposed as a signalling molecule regulating cellular responses, including synaptic vesicle release, 
mast cell degranulation, phagocytosis, inflammation and proliferation [11]. The only direct 
target of C1P described so far is cytosolic cPLA2, which was shown to directly bind C1P at 
its calcium-dependent lipid-binding (CaLB) domain and is activated upon C1P binding [12]. 
C1P is generated by the action of a ceramide kinase (CerK), which was cloned from 
various species including human and mouse [13]. The enzyme shows sequence homology 
to diacylglycerol kinase and sphingosine kinase, and contains a N-terminal myristoylation 
site and a pleckstrin homology domain, which both seem to be indispensable for membrane 
association. The enzyme is localized at various subcellular sites including Golgi, cytoplasm 
and nucleus [14, 15]. Since the N-terminal sequence of CerK contains a nuclear import signal 
and the C-terminal sequence contains a nuclear export signal [15], it was speculated that nucleocytoplasmic shuttling of CerK occurs and that CerK is active both inside and outside 
of the nucleus. 
Here, we investigated the cellular function of CerK in renal mesangial cells and in 
renal fibroblasts. We demonstrate that in neither cell type, inhibition of CerK using the 
novel catalytic inhibitor NVP-231 attenuated agonist-stimulated arachidonic acid release or PGE2 formation, thus, excluding its role in inflammation. However, we instead report 
that inhibition of CerK decreases cell proliferation by induction of M phase arrest and 
apoptosis, and facilitates apoptosis induced by various stress stimuli. Our data suggest that 
pharmacological inhibition of CerK has potential for treating proliferation-associated kidney 
diseases such as in mesangioproliferative glomerulonephritis and renal cancer.
Materials and Methods
Chemicals[3H]-arachidonic acid (specific activity: 180-240 Ci/mmol) and [6-3H]-thymidine (specific activity: 10 
Ci/mmol) were from Hartmann Analytic GmbH, Braunschweig, Germany; the PGE2 ELISA was from Enzo 
Life Sciences, Lörrach, Germany; the Cell Death Detection ELISAPLUS was from Roche Diagnostics, Mannheim, 
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Germany; secondary horseradish peroxidase-coupled IgGs, Hyperfilm MP and enhanced chemiluminescence 
reagents were from GE Health Care Systems, Glattbrugg, Switzerland. Human recombinant IL-1β was 
from Cell Concept, Umkirch, Germany; TNF-α was a gift from Knoll AG, Ludwigshafen, Germany; PDGF-
BB was kindly provided by Dr. Michael Pech, F.Hoffmann-La Roche Ltd., Basel, Switzerland; antibodies 
against glyceraldehyde 3-phosphate dehydrogenase (GAPDH), total histone H3, cleaved caspase-3, PARP-1, 
phospho-Tyr15-cdc2, total cdc2, phospho-Ser133-cyclin B1, total cyclin B1, phospho-Thr210-PLK1, and total 
PLK1 were obtained from Cell Signaling, Schwalbach, Germany; COX2 and  β-actin were from Santa Cruz 
Biotechnology Inc., Heidelberg, Germany; phospho-Ser10-histone H3 was from EMD Millipore Corporation; 
ATP, TPA, ionomycin, forskolin, and NVP-231 were obtained from Sigma Aldrich Fine Chemicals, Buchs, 
Switzerland; all cell culture additives were from Invitrogen AG, Basel, Switzerland.
Cell culture and stimulation
Rat glomerular mesangial cells were isolated, characterized and cultured as described [16]. CerK 
deficient mice were kindly provided by Dr. Bornancin (Novartis Pharma AG, Basel) [17]. Mouse renal 
fibroblasts were isolated from wildtype BalbC mice or CerK deficient mice as described [18] and plated 
on collagen-coated plastic dishes. Rat cells were cultivated in RPMI medium supplemented with 10 % fetal 
bovine serum (FBS), 10 mM HEPES pH 7.4, 6 µg/ml bovine insulin, 5 µg/ml transferrin, 5 ng/ml sodium 
selenite, 100 units/ml penicillin, and 100 µg/ml streptomycin. Mouse cells were cultivated in the same 
medium but additionally supplemented with 1% non-essential amino acids and 45 µM β-mercaptoethanol. 
All cells were grown at 370C in a humidified atmosphere containing 5 % CO2. 
Cell homogenization and Western blot analysis 
After treatment cells were washed with phosphate-buffered saline (PBS), scraped and homogenized 
in lysis buffer [19] and centrifuged for 10 min at 13’000 x g. The supernatant was taken for protein 
determination and 30 µg of protein was separated by SDS–PAGE, transferred to nitrocellulose membrane 
and immunostained using antibodies as indicated in the figure legends.
Determination of arachidonic acid release 
Confluent cells in 24-well plates were labelled for 24 h with 1 µCi/ml of [3H]-arachidonic acid 
in Dulbecco’s modified Eagle medium (DMEM) containing 0.1 mg/ml of fatty acid-free bovine serum 
albumin (BSA). Cells were then washed three times with DMEM containing 1 mg/ml of BSA to remove all 
unincorporated arachidonic acid. Thereafter, cells were stimulated as indicated and the supernatant was 
taken for determination of released radioactivity. 
Determination of DNA synthesis 
To measure DNA synthesis in cells, the incorporation of [3H]-thymidine into de novo synthesized DNA 
was detected as described [19].
Cell cycle analysis by flow cytometry.
 Cells were harvested by trypsinization, washed and fixed in 70 % ethanol for at least 1 h at -20°C. 
30 min prior to analysis, cells were resuspended in PBS containing 50 µg/ml propidium iodide and 1 mg/
ml RNase A in PBS. Cell cycle distribution was analyzed using a FACSCalibur flow cytometer and the Cell 
Quest software (both from Becton Dickinson Biosciences, Allschwil, Switzerland). At least 20’000 cells were 
counted for each sample.
Determination of apoptosis 
Cells in 96-well plates were stimulated as indicated and directly taken for detection of DNA 
fragmentation using a Cell Death detection ELISAPLUS (Roche Diagnostics, Mannheim, Germany) according to 
the manufacturer’s instructions.
C16-ceramide and sphingosine quantification by LC-MS/MS 
Stimulated cells in 6-well plates were scraped into methanol containing internal C17-ceramide and 
C17-sphingosine standards and subjected to lipid extraction and LC/MS/MS analysis as described [20]. 
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Statistical analysis 
Statistical analysis of data was performed using one-way ANOVA following Bonferroni post-hoc test 
for multiple comparisons or unpaired t-tests when only two groups were compared.
Results 
CerK inhibition does not abrogate agonist-induced arachidonic acid release or PGE2 
formation in renal mesangial cells
It was previously suggested that C1P is involved in cPLA2 activation by directly binding 
and activating the enzyme [12]. To investigate this further, we measured the effect of CerK on 
cPLA2 activation in rat renal mesangial cells using a novel potent catalytic inhibitor of CerK, 
NVP-231 [21]. This inhibitor demonstrated an in vitro IC
50
 value for CerK of 12 nM [21]. NVP-
231 competitively binds to the ceramide binding site of the enzyme, is highly cell-permeable 
and active under intracellular conditions [21].
As a cellular activity assay of cPLA2, the release of [3H]-arachidonic acid upon agonist 
stimulation was detected. [3H]-arachidonic acid-labelled cells were stimulated with either 
extracellular ATP or platelet-derived growth factor-BB (PDGF-BB), two well-known cellular 
cPLA2 activators acting via the P2Y2 purinoceptor or PDGFRβ, respectively. Both agonists 
stimulated a pronounced arachidonic acid release after 30 min of stimulation (Fig. 1A and 
1B). In the presence of NVP-231 no reduction of [3H]-arachidonic acid release was observed 
upto 3 µM as the highest concentration tested. 
Additional stimuli were also tested including serum, 12-O-tetradecanoylphorbol 
13-acetate (TPA), ionomycin and the combination of TPA plus ionomycin. Whereas 
Fig. 1. Effect of NVP-231 on agonist-stimulated arachidonic acid release in rat renal mesangial cells. [3H]-
arachidonic acid-labelled rat mesangial cells were stimulated for 1 h with either vehicle (Co), 100 µM of ATP 
(A), 20 ng/ml of PDGF-BB (B), 10 % FBS (C), TPA (100 nM) (D), ionomycin (1 µM) (D) or a combination of 
TPA plus ionomycin (D) in the absence or presence of the indicated concentrations of NVP-231. Released 
3H-arachidonic acid was determined as described in the Methods Section. Data are expressed as % of control 
and are means ±S.D. (n=4). *p<0.05, **p<0.01, ***p<0.001 considered statistically significant when com-
pared to the control values; ###p< 0.001 when compared to the TPA plus ionomycin-stimulated value.
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stimulation of cells with 10 % FBS induced strong [3H]-arachidonic acid release (Fig. 1C), 
TPA alone or ionomycin alone exerted only marginal effects and only the combination of 
TPA plus ionomycin was synergistically active (Fig. 1D). This confirms previous findings 
that phosphorylation of cPLA2 by the protein kinase C/MAPK cascade alone, or increased intracellular Ca2+ alone is not sufficient to fully activate cPLA2, and that only the combination of phosphorylation and increased Ca2+ fully activates cPLA2 [22, 23]. Again, in the presence of 
NVP-231 no reduction of either serum, TPA or ionomycin-induced arachidonic acid release 
was found. The combined stimulation with TPA plus ionomycin was even enhanced in the 
presence of NVP-231. Our data thus demonstrate that cPLA2 activity induced by the various 
stimuli described above is not abrogated by CerK inhibition, a finding which questions the 
current hypothesis that C1P is necessary for cPLA2 activity.
We also stimulated rat mesangial cells for 24 h with the pro-inflammatory cytokine 
IL-1β which is known to induce PGE2 synthesis in these cells by combined induction and 
activation of cPLA2 and group IIA sPLA2 [24, 25]. Again, as shown in Fig. 2A, in the presence 
of low concentrations of NVP-231, PGE2 formation was not reduced (Fig. 2A), whereas it was 
even enhanced at higher concentrations (1-5 µM). Analogous to the increased PGE2, COX2 
protein expression was also upregulated (Fig. 2B). Increased PGE2 synthesis (Fig. 2C) was 
also seen when cells were exposed to IL-1β in the presence of increasing concentrations of C
6
-ceramide suggesting that ceramide, which is expected to accumulate upon CerK inhibition, 
is responsible for the increased PGE2 formation. 
We next investigated what effect the complete genetic knockout of CerK has on arachidonic acid release and PGE2 formation in mouse renal fibroblasts isolated from CerK 
(-/-) mice and control littermates (Wt). As shown in Fig. 3A, CerK knockout had no effect 
Fig. 2. Effect of NVP-231 on cy-
tokine-stimulated PGE2 forma-
tion in rat renal mesangial cells. Rat mesangial cells were stimu-
lated for 24 h with either vehicle 
or IL-1β (2 nM) in the absence or presence of the indicated con-
centrations of NVP-231 (A, B), or C
6
-ceramide (C). Supernatants 
were taken for PGE2 quantifica-tion using a PGE2-ELISA (A and 
C). Protein in the remaining cell monolayer were extracted and 
taken for Western blot analy-sis (B) of COX2 (upper panel) or β-actin (lower panel). Data 
in A and C are expressed as pg/ml supernatant and are means 
±S.D. (n=4). ***p<0.001 con-
sidered statistically significant when compared to the control 
values; #p< 0.05, ###p< 0.001 
when compared to the the IL-1β-
stimulated values.
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on the various agonists-triggered arachidonic acid release including TPA, ionomycin, the 
combination of TPA plus ionomycin, ATP and serum.  Also, no difference in IL-1β-stimulated PGE2 synthesis was observed in CerK (-/-) cells (Fig. 3B). 
Altogether, our data do not confirm previous findings that CerK is positively involved 
in cPLA2 activation and subsequent PGE2 formation, but rather suggest the ability of the 
substrate ceramide to stimulate arachidonic acid release and promote COX-2 induction and 
subsequent PGE2 formation.
Fig. 3. Effect of CerK knockout on agonist-stimulated 
arachidonic acid release in mouse renal fibroblasts. 
(A)Mouse renal fibroblasts isolated from either 
wildtype BalbC mice (Wt, open columns) or CerK 
deficient mice (CerK(-/-), closed columns) were la-
belled for 24 h with [3H]-arachidonic acid and there-after stimulated for 1 h with either vehicle (Co), TPA (100 nM), ionomycin (iono, 1 µM), TPA (100 nM) plus ionomycin (1 µM), ATP (100 µM), or fetal bo-
vine serum (FBS, 10 %). Samples were processed as 
described in the Methods Section. (B) Mouse renal 
fibroblasts isolated from either wildtype BalbC mice 
(Wt, open columns) or CerK deficient mice (CerK 
(-/-), closed columns) were stimulated for 24 h with 
either vehicle (Co) or IL-1β (1 nM). Supernatants 
were taken for a PGE2 ELISA. Data are expressed as 
% of control and are means ± S.D. (n=4). *p<0.05, 
**p<0.01, ***p<0.001 considered statistically signifi-
cant when compared to the control values; ##p< 0.01 
when compared to the CerK (-/-) values.
Fig. 4. Effect of NVP-231 on ATP- and serum-stimu-
lated mesangial cell proliferation. Quiescent rat me-
sangial cells were stimulated for 24 h with ATP (100 
µM, A) or 48 h with PDGF-BB (20 ng/ml, B) in the 
absence or presence of the indicated concentrations 
of NVP-231 (in µM) and in the presence of [3H]-thy-
midine. Samples were processed as described in the 
Methods Section. Data are expressed as % of control 
and are means ±S.D. (n=4).  **p<0.01, ***p<0.001 
considered statistically significant when compared 
to the control values.  ##p<0.01, ###p<0.001 when 
compared to the agonist-stimulated value.
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Inhibition of CerK decreases proliferation of renal mesangial cells and fibroblasts
A major biological function attributed to CerK is stimulation of cell proliferation 
[11]. Since mesangial cell proliferation is an important hallmark of many forms of chronic 
Fig. 5. Effect of NVP-231 and of CerK gene knockout on proliferation of mouse renal fibroblasts. (A) 
Renal fibroblasts isolated from BalbC mice were treated for 24 h with either vehicle (Co) or the indicated 
concentrations of NVP-231 in the presence of [3H]-thymidine. (B) 104 cells of renal fibroblasts from wildtype 
BalbC mice (Wt, open circles) and from CerK knockout mice (CerK (-/-), closed squares) were seeded in the presence of [3H]-thymidine and DNA synthesis was measured after 72 h, 96 h, and 120 h. Samples were 
processed as described in the Methods Section. Data are expressed as % of control (A) or as cpm/well (B) 
and are means ± S.D. (n=4).  *p<0.05, ***p<0.001 considered statistically significant when compared to the 
respective control values. 
BA
Fig. 6. Effect of NVP-231 on cell cycle distribution of rat renal mesangial cells. Rat mesangial cells were 
incubated for 24 h in growth medium containing either vehicle (control) (A) or 10 µM of NVP-231 (B). Cells 
were stained with propidium iodide and DNA content was measured by flow cytometry using a FACSCalibur 
flow cytometer and the Cell Quest software for data processing. The graphs in A and B are representative 
of three independent experiments. (C) shows the % of total cells in the different cell cycle phases of control 
cells (open columns) and NVP-231-treated cells (closed columns) and are means ± S.D. (n=3). **p<0.01, 
***p<0.001 considered statistically significant when compared to the corresponding Wt values.
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inflammatory kidney diseases [1-3], we investigated whether inhibition of CerK using NVP-
231 affects mesangial cell growth determined by [3H]-thymidine incorporation. To this end, 
quiescent rat renal mesangial cells were stimulated with two well-known mitogens, i.e. 
extracellular ATP and PDGF-BB. As shown in Fig. 4A, ATP stimulated DNA synthesis already 
after 24 h. In the presence of NVP-231, this effect was dose-dependently decreased and 
resulted in almost complete inhibition at a dose of 3 µM NVP-231. PDGF-BB was a weaker 
mitogen for which 48 h of stimulation was required to increase DNA synthesis (Fig. 4B). 
Again, this effect was dose-dependently decreased by NVP-231 (Fig. 4B). 
Similar to rat renal mesangial cells, a dose-dependent anti-proliferative effect of NVP-
231 was also observed in mouse renal fibroblasts (Fig. 5A). Furthermore, we found that the 
Fig. 7. Effect of NVP-231 on phospho-histone H3, cdc2, cyclin B1 and PLK1 expression in rat mesangial cells. 
Rat mesangial cells were incubated for 24 h in growth medium in the absence or presence of the indicated concentrations (in µM) of NVP-231. Thereafter, cell lysates were prepared and proteins were separated by 
SDS-PAGE, transferred to nitrocellulose membranes and subjected to Western blot analysis using antibod-
ies against phospho-histone H3 (A), total histone H3 (A), phospho-Tyr15-cdc2 (A), total cdc2 (A), phospho-cyclin B1 (A), total cyclin B1 (A), β-actin (A), phospho-PLK1 (B), and total PLK1 (B). A representative blot 
from two independent experiments performed in duplicates is shown. 
Fig. 8. Effect of NVP-231 on PARP-1 cleavage in rat mesangial cells. Rat mesangial cells were treated for 
24h with either vehicle (Co) or the indicated concentrations of NVP-231. Protein lysates were prepared 
and samples were separated by SDS-PAGE, transfer to nitrocellulose and subjected to Western blot analysis 
using antibodies against PARP-1 (upper panel) or GAPDH (lower panel). A representative blot from two 
independent experiments performed in duplicates is shown.
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proliferation rate of CerK (-/-) fibroblasts detected over 6 days in culture was significantly 
lower compared to wildtype fibroblasts (Fig. 5B). 
We next investigated whether CerK inhibition and decreased proliferation was 
associated with altered cell cycle distribution. To this end, rat mesangial cells were treated 
for 24 h with NVP-231 and the DNA content was determined. Strikingly, as shown in Fig. 6, 
upon NVP-231 treatment, the number of cells in G1 (2N DNA content) and S phase (2N>4N) 
decreased and cells accumulated in G2/M (4N DNA content). At the same time, also the 
number of cells with fragmented DNA (sub G1 peak) and of polyploid cells with a 8N DNA 
content increased (Fig. 6C). 
To more specifically investigate whether cells accumulated at the G2/M boundary or 
were arrested in the M phase, lysates of NVP-231-treated cells were subjected to Western 
blot analysis and stained for cell cycle markers relevant for M phase regulation. As shown 
in Fig. 7A, the level of the mitosis marker phospho-histone H3 increased dose-dependently 
upon NVP-231 treatment indicating that cells were mainly arrested in M phase. The amount 
of total histone H3 remained unchanged (Fig. 7A). Furthermore, we determined the level of 
cdc2 (CDK1) as a major regulator of G2-M transition and execution of mitosis [26, 27]. Cdc2 
interacts wih cyclin B1 in a complex which is kept in an inactive state by Tyr15 phosphorylation 
of cdc2. At the G2/M boundary, cdc2 is dephosphorylated and thereby activated to promote 
mitotic entry. Here, we found that cdc2 Tyr15 phosphorylation was decreased upon NVP-231 
treatment which further suggests that cells entered mitosis (Fig. 7A). No change of cyclin 
B1 was seen neither on the level of phosphorylation nor total protein expression (Fig. 7A). 
However, we found that treatment with NVP-231 also increased the phosphorylation and 
thus activation of polo-like kinase 1 (PLK1) (Fig. 7B), a kinase regulating mitosis entry and 
Fig. 9. Effect of CerK knockout on staurosporine- and TNFα/cycloheximide-induced apoptosis in renal fi-
broblasts. Mouse renal fibroblasts isolated from wildtype BalbC mice (Wt, open columns) or CerK-deficient 
mice (CerK (-/-), closed columns) were treated for 2 h  with either vehicle (Co) and staurosporine (30 nM) 
(A and C), or for 24 h with vehicle (Co) and TNFα (1 nM) plus cycloheximide (10 µM) (B and D). Samples 
were taken for a DNA fragmentation ELISA (A and B). Protein lysates were taken for SDS-PAGE, transfer to 
nitrocellulose and Western blot analysis (C and D) using antibodies against PARP-1 (upper panels), cleaved 
caspase-3 (middle panels) and β-actin (lower panels). Data in A and B are expressed as % of control values 
and are means ± S.D. (n=3). *p<0.05, ***p<0.001 considered statistically significant when compared to the 
wildtype control values. ###p<0.001 when compared to the CerK (-/-) control values, §§p<0.01 when com-
pared to the Wt stauro- (in A) or Wt TNFα/CHX (in B)-stimulated values respectively.
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bipolar spindle assembly [28]. Cells remaining in the sub G1 phase upon NVP-231 treatment 
underwent classical apoptosis as further confirmed by increased poly-(ADP-ribose)-
polymerase-1 (PARP-1) cleavage [29] shown in Fig. 8.
To investigate whether knockout of CerK in renal fibroblasts also facilitated apoptosis, 
DNA fragmentation detected by ELISA was measured in the presence of either staurosporine or TNFα/cycloheximide, two well-known inducers of apoptosis. As expected, both treatments 
induced DNA fragmentation (Fig. 9A and B) and this effect was significantly increased in 
CerK (-/-) fibroblasts (Fig. 9A and B). Concomitantly, cleavage of caspase-3 and PARP-1 was 
increased compared to wildtype cells (Fig. 9C and D). 
Finally, to verify that in rat mesangial cells, CerK inhibition by NVP-231 results in 
the accumulation of cellular ceramide, the main ceramide subspecies C
16
-ceramide, and 
sphingosine for comparison, were quantified by mass spectrometry. As shown in Fig. 10, C
16
-ceramide indeed dose-dependently increased from basal 18 ± 1.5 ng/ 106 cells to 39 ± 
3.1 ng/ 106 cells upon treatment with 10 µM NVP-231, whereas sphingosine levels were not 
significantly changed. 
Discussion
To date, the cellular function of CerK is still a matter of debate. Various studies 
demonstrated that CerK is an essential enzyme to produce C1P which, in turn, directly binds 
to and activates cPLA2 resulting in the synthesis of pro-inflammatory PGE2. These data unveil 
a key role for CerK in inflammation and suggest CerK targeting as a treatment modality for 
inflammatory diseases [30, 31]. However, data from CerK gene deficient mice do not support 
this hypothesis, since the loss of CerK did not ameliorate disease symptoms in inflammation-
related disease models such as arthritis, peritonitis, thrombocytopenic purpura, and active 
or passive cutaneous anaphylaxis models [17]. Moreover, in a mouse model of fulminant 
pneumonia, CerK deficient mice showed even more severe symptoms and increased mortality. 
The lack of effect of CerK gene knockout in most of these experimental disease models may 
be due to systemic compensatory mechanisms to restore C1P homeostasis. Conflicting data 
were also reported from cells isolated from CerK (-/-) mice. On the one hand, Graf et al. 
[17] found no change of agonist-induced arachidonic acid release and PGE2 formation in 
CerK (-/-) peritoneal macrophages compared to wildtype macrophages which fits well to 
our data. On the other hand, using mouse embryonic fibroblasts and bone marrow-derived 
macrophages from the same CerK (-/-) mouse strain, Mietla et al. [32] reported considerably 
decreased formation of arachidonic acid and various prostaglandin subspecies measured 
by mass spectrometry. The reason for this discrepancy is unclear. Similarly, as shown in 
RAG1-deficient mice, the additional depletion of CerK resulted in lower basal PGE2 levels 
in bronchoalveolar lavage fluid [33]. However, upon ovalbumin stimulation as a model of 
experimentally-induced asthma, the induction of PGE2 synthesis was manifold higher in 
Fig. 10. Effect of NVP-231 on C
16
-ceramide 
and sphingosine levels in rat mesangial cells. 
Rat mesangial cells were treated for 24 h with either vehicle (Co) or the indicated 
concentrations of NVP-231. Lipids were ex-
tracted as described in the Methods Section 
and quantified by LC-MS/MS. Sphingosine (open columns) and C
16
-ceramide (closed 
columns) are expressed as ng/ 106 cells and 
are means ± S.D. (n=3). ***p<0.001 consid-
ered statistically significant when compared 
to the wildtype control values.
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CerK (-/-) compared to CerK (+/+) mice, whereas the total amount of PGE2 reached by 
ovalbumine stimulation was still identical in the two mouse strains as was the severity of 
disease symptoms [33].
An alternative approach to overcome potential compensatory mechanisms of CerK 
gene knockout is the use of catalytic CerK inhibitors. Such an inhibitor, NVP-231, has been 
developed recently which demonstrated an in vitro IC
50
 value for CerK of 12 nM [21]. The 
inhibitor proved to be highly cell-permeable and active under intracellular conditions 
[21]. Using NVP-231 in renal mesangial cells, we could clearly demonstrate that inhibition 
of CerK activity does not decrease either arachidonic acid release or PGE2 formation in 
renal mesangial cells. Rather, we found an increase of PGE2 (Fig. 2A) as a consequence of 
upregulated COX2 protein (Fig. 2B). This finding may be mechanistically explained by an 
increase of intracellular ceramide upon CerK inhibition (Fig. 10). 
In fact, ceramide has been discussed as a pro-inflammatory lipid for many years. 
Mechanistically, ceramide was on the one hand shown to activate cPLA2 [34-36] and also 
to enhance the expression of sPLA2 [37] and COX2 [38-40] in various cell types, including 
mesangial cells and fibroblasts. Furthermore, in several inflammation-related disease 
models, ceramide was shown to contribute to an inflammatory phenotype such as in cystic 
fibrosis [41], pulmonary emphysema [42], and other acute and chronic lung injuries [43]. 
Whatever the pro-inflammatory mechanism of ceramide is, our data strongly suggest that 
CerK is not a suitable target for the treatment of inflammation and that its inhibition may 
result in the opposite effect i.e. acceleration of PGE2 formation, which worsens symptoms 
even further. 
Here we found that inhibition of CerK in renal mesangial cells using NVP-231 reduced 
proliferation and sensitized cells to stress-induced apoptosis. 
A role for CerK in the regulation of apoptosis was first proposed by Liang et al. [44] who showed that in Arabidopsis, mutation of the plant homolog of CerK, also denoted “accelerated 
cell death 5” (acd5), not only led to an accumulation of ceramides, but also increased calcium 
mobilization and cell death upon pathogen infection [44, 45]. Similarly, downregulation 
of CerK using RNA interference was shown to inhibit proliferation and enhance apoptosis 
also in human A549 lung adenocarcinoma cells [46]. Apart from these preclinical findings, 
evidence for a key role of CerK in tumor progression was reported by Ruckhäberle et al. 
[47], who demonstrated that high CerK expression in tumor tissues correlated with a worse 
prognosis in patients with estrogen receptor-negative breast cancer. Moreover, recent data 
also suggest that the CerK protein is upregulated as a hormetic response of hepatoma cells 
exposed to UV irradiation to evade apoptosis, which could be counteracted by CerK silencing 
[48]. Based on this observation, pharmacological inhibition of CerK was suggested as a new 
concept in hepatoma therapy. The anti-proliferative and pro-apoptotic potential of CerK 
targeting is also corroborated by our data from CerK (-/-) fibroblasts demonstrating that the 
loss of CerK facilitates apoptosis induced by stress factors such as staurosporine or TNFα 
combined with cycloheximide (Fig. 9). 
Further evidence that CerK targeting to decrease cell proliferation and survival may 
have therapeutic potential also derived from studies were CerK activity was affected 
indirectly. For instance, the anti-proliferative effect of vitamin D
3
 on neuroblastoma cells 
was shown to involve the downregulation of CerK and C1P by vitamin D
3
 [49], and CerK 
downregulation was also involved in all-trans retinoic acid (ATRA)-induced differentiation 
of neuroblastoma cells [50]. In mouse keratinocytes, it was correspondingly shown that the 
peroxisome proliferator-activated receptor β (PPARβ) promoted cell survival, which was dependent on PPARβ-mediated upregulation of CerK [51]. Consequently, in CerK deficient mice, PPARβ-mediated keratinocyte survival was strongly decreased [51]. These findings 
together with our data strongly support a key role for CerK in cell proliferation and survival. 
Here, we report that in mesangial cells inhibition of CerK using NVP-231 induced M 
phase arrest and subsequent apoptosis. M phase arrest was confirmed by various parameters, including reduced Tyr15 phosphorylation of cdc2, reflecting enhanced cdc2 activity and 
mitotic entry, and enhanced phospho-histone H3 as a marker of mitosis. Furthermore, 
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treatment with NVP-231 increased the phosphorylation and thus activity of PLK1, a kinase 
regulating mitosis progression and proper bipolar spindle assembly [28]. 
This finding raises the intriguing question how CerK inhibition converges to the cell 
cycle machinery and whether the observed M phase arrest was due to ceramide accumulation 
or lack of C1P. That ceramide production is increased in CerK (-/-) mice and isolated cells 
was previously reported [17, 32]. Here, we confirm the accumulation of ceramide also in 
cells treated with NVP-231 (Fig. 10). In fact, ceramide is a well-characterized lipid with 
anti-proliferative and pro-apoptotic activity [9, 41]. Although the target of ceramide within 
the cell cycle machinery is still a matter of debate, it was shown to stimulate G1 arrest by 
inducing dephosphorylation of the retinoblastoma protein (Rb) [52, 53] and upregulation of 
the CDK inhibitory factor p21Cip1 [53, 54]. On the other hand, there is evidence that ceramide 
accumulation correlates with G2/M arrest [55-57]. This ambivalent effect may be due to 
cell type-specific differences in the equipment with ceramide-converting enzymes, such as 
sphingomyelin synthase, glucosylceramide synthase, ceramidases, and sphingosine kinases, 
all of which are essential determinants of ceramide action [58-61]. 
Alternatively, the here reported cell cycle effect may be attributed to the loss of C1P, 
which raises the question where in the cell C1P is generated. Based on the presence of nuclear 
import and export signals in the CerK sequence, both nuclear and cytoplasmic localizations 
were suggested [15]. Moreover, in COS-1 cells transfected with green fluorescence protein 
(GFP)-tagged CerK the enzyme was shown to localize in the cytoplasm, the nucleus and the 
nucleolus [15]. Further investigations are therefore warranted to reconcile the subcellular 
localization of CerK with the putative site of C1P activity and its link to cell cycle regulation.
In summary, we demonstrated here that CerK induces proliferation, but not PGE2 
formation, in renal mesangial cells and fibroblasts, and that its pharmacological inhibition 
has potential for the treatment of proliferative kidney diseases, but not for renal diseases 
associated with inflammation. 
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